![The Difference in Prognostic Outcomes Between De Novo Stage IV and Recurrent Metastatic Patients with Hormone Receptor-positive, HER2-negative Breast Cancer | In Vivo The Difference in Prognostic Outcomes Between De Novo Stage IV and Recurrent Metastatic Patients with Hormone Receptor-positive, HER2-negative Breast Cancer | In Vivo](https://iv.iiarjournals.org/content/invivo/32/2/353/F3.large.jpg)
The Difference in Prognostic Outcomes Between De Novo Stage IV and Recurrent Metastatic Patients with Hormone Receptor-positive, HER2-negative Breast Cancer | In Vivo
![Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-022-01845-z/MediaObjects/41416_2022_1845_Fig1_HTML.png)
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
![Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics | British Journal of Cancer Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2014.5/MediaObjects/41416_2014_Article_BFbjc20145_Fig1_HTML.jpg)
Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics | British Journal of Cancer
![Frontiers | A Risk Stratification Model for Predicting Overall Survival and Surgical Benefit in Triple-Negative Breast Cancer Patients With de novo Distant Metastasis Frontiers | A Risk Stratification Model for Predicting Overall Survival and Surgical Benefit in Triple-Negative Breast Cancer Patients With de novo Distant Metastasis](https://www.frontiersin.org/files/MyHome%20Article%20Library/512973/512973_Thumb_400.jpg)
Frontiers | A Risk Stratification Model for Predicting Overall Survival and Surgical Benefit in Triple-Negative Breast Cancer Patients With de novo Distant Metastasis
![Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge | npj Breast Cancer Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge | npj Breast Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41523-021-00269-x/MediaObjects/41523_2021_269_Fig1_HTML.png)
Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge | npj Breast Cancer
![Survival after diagnosis of metastatic breast cancer for patients with... | Download Scientific Diagram Survival after diagnosis of metastatic breast cancer for patients with... | Download Scientific Diagram](https://www.researchgate.net/publication/281546004/figure/fig1/AS:270939829043216@1441608497585/Survival-after-diagnosis-of-metastatic-breast-cancer-for-patients-with-de-novo-metastatic.png)
Survival after diagnosis of metastatic breast cancer for patients with... | Download Scientific Diagram
![Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology](https://www.thelancet.com/cms/asset/28f62488-d818-4e72-ba24-1636b3b8d894/gr1.jpg)
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology
![The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-6311-z/MediaObjects/12885_2019_6311_Fig2_HTML.png)
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer | BMC Cancer | Full Text
![Ten-year conditional recurrence risks and overall and relative survival for breast cancer patients in the Netherlands: Taking account of event-free years - ScienceDirect Ten-year conditional recurrence risks and overall and relative survival for breast cancer patients in the Netherlands: Taking account of event-free years - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804918310931-gr2.jpg)
Ten-year conditional recurrence risks and overall and relative survival for breast cancer patients in the Netherlands: Taking account of event-free years - ScienceDirect
![Identifying the potential long-term survivors among breast cancer patients with distant metastasis - Annals of Oncology Identifying the potential long-term survivors among breast cancer patients with distant metastasis - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8e5bba71-60ac-4739-8f50-38f618e1b6ba/gr1.jpg)